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Caregiver Health-Related Quality of
Life, Burden, and Patient Outcomes in
Ambulatory Advanced Heart Failure: A
Report From REVIVAL
Nisha A. Gilotra , MD; Salpy V. Pamboukian, MD, MSPH; Maria Mountis, DO; Shawn W. Robinson, MD;
Michelle Kittleson , MD, PhD; Keyur B. Shah, MD; Rhondalyn C. Forde-McLean, MD, MHS;
Donald C. Haas, MD; Douglas A. Horstmanshof, MD; Ulrich P. Jorde , MD; Stuart D. Russell, MD;
Wendy C. Taddei-Peters, PhD; Neal Jeffries, PhD; Shokoufeh Khalatbari, MS; Catherine A. Spino, ScD;
Blair Richards, MPH; Matheos Yosef, PhD; Douglas L. Mann , MD, PhD; Garrick C. Stewart, MD, MPH;
Keith D. Aaronson , MD, MS; Kathleen L. Grady , PhD
BACKGROUND: Heart failure (HF) imposes significant burden on patients and caregivers. Longitudinal data on caregiver health-
related quality of life (HRQOL) and burden in ambulatory advanced HF are limited.

Downloaded from http://ahajournals.org by on August 12, 2021

METHODS AND RESULTS: Ambulatory patients with advanced HF (n=400) and their participating caregivers (n=95) enrolled in
REVIVAL (Registry Evaluation of Vital Information for VADs [Ventricular Assist Devices] in Ambulatory Life) were followed up for
24 months, or until patient death, left ventricular assist device implantation, heart transplantation, or loss to follow-up. Caregiver
HRQOL (EuroQol Visual Analog Scale) and burden (Oberst Caregiving Burden Scale) did not change significantly from baseline to follow-up. At time of caregiver enrollment, better patient HRQOL by Kansas City Cardiomyopathy Questionnaire was
associated with better caregiver HRQOL (P=0.007) and less burden by both time spent (P<0.0001) and difficulty (P=0.0007)
of caregiving tasks. On longitudinal analyses adjusted for baseline values, better patient HRQOL (P=0.034) and being a married caregiver (P=0.016) were independently associated with better caregiver HRQOL. Patients with participating caregivers
(versus without) were more likely to prefer left ventricular assist device therapy over time (odds ratio, 1.43; 95% CI, 1.03–1.99;
P=0.034). Among patients with participating caregivers, those with nonmarried (versus married) caregivers were at higher
composite risk of HF hospitalization, death, heart transplantation or left ventricular assist device implantation (hazard ratio,
2.99; 95% CI, 1.29–6.96; P=0.011).
CONCLUSIONS: Patient and caregiver characteristics may impact their HRQOL and other health outcomes over time.
Understanding the patient-caregiver relationship may better inform medical decision making and outcomes in ambulatory
advanced HF.
Key Words: caregiving ■ heart failure ■ left ventricular assist device ■ quality of life

H

eart failure (HF) is a time intensive chronic condition heavily reliant on self-care to maintain health
and manage symptoms of congestion, thus imposing significant burden on patients and their caregivers.1–3 Caregivers play a critical role in daily HF

disease management tasks, as well as logistical support for care coordination, emotional support, and participation in complex medical decision making.4,5 As
HF progresses, patients often become more reliant on
caregivers, who may experience an increased sense
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CLINICAL PERSPECTIVE
What Is New?

• In an ambulatory cohort of patients with advanced heart failure, we found that surviving
patients’ health-related quality of life improved
modestly over time and that caregivers’ health-
related quality of life and burden did not change.
• Having a participating, married caregiver was
associated with an increased patient willingness to consider ambulatory left ventricular assist device therapy and a lower composite risk
of death, urgent transplant, or left ventricular assist device therapy.

What Are the Clinical Implications?

• Caregivers play a fundamental role in the lives of
patients with advanced heart failure; however,
their impact on clinical outcomes is not commonly considered.
• These data highlight the need for including
caregiver perspective and presence when assessing patient longitudinal outcomes and
understanding shared decision making in advanced heart failure.
• Efforts are needed to increase caregiver participation in clinical studies to better understand
the important role of the caregiver in heart
failure.
Downloaded from http://ahajournals.org by on August 12, 2021

Existing studies of patients with HF and their caregivers have focused primarily on caregivers of patients undergoing advanced HF therapies, such as left
ventricular assist device (LVAD) implantation or heart
transplantation.10–12 Despite a recognized association
between caregiver HRQOL and patient outcomes, longitudinal data on burden and HRQOL for caregivers of
patients with advanced HF are lacking.13 Furthermore,
to our knowledge, burden and HRQOL have not been
examined in caregivers of ambulatory patients with
advanced HF. REVIVAL (Registry Evaluation of Vital
Information for VADs [Ventricular Assist Devices] in
Ambulatory Life) provides an opportunity to study
caregiver burden and HRQOL over time in an ambulatory advanced HF cohort. The purposes of our report
from REVIVAL are to: (1) examine change in caregiver
HRQOL and burden over time compared with patient
HRQOL, (2) identify patient and caregiver factors related to caregiver HRQOL and burden, and (3) examine whether caregiver factors are related to patient
HRQOL, preference for LVAD therapy, and clinical outcomes. We hypothesized that (1) advanced HF patient
HRQOL and caregiver HRQOL will decline over time,
whereas caregiver burden will increase over time, (2)
both caregiver characteristics (eg, high perceived burden) and patient characteristics (eg, poor HRQOL) will
be related to caregiver HRQOL, whereas patient characteristics (eg, worse HF and worse patient HRQOL)
will be related to increased caregiver burden, and (3)
caregiver characteristics (eg, being a spouse or partner) will be related to patient preference for LVAD therapy and patient clinical outcomes.

Nonstandard Abbreviations and Acronyms
EQ-VAS
INTERMACS

KCCQ
OCBS
REVIVAL

EuroQol Visual Analog Scale
Interagency Registry for
Mechanically Assisted Circulatory
Support
Kansas City Cardiomyopathy
Questionnaire
Oberst Caregiving Burden Scale
Registry Evaluation of Vital
Information for VADs (Ventricular
Assist Devices) in Ambulatory Life

of burden as support needs increase6 or change in
health-related quality of life (HRQOL).7 In addition, as
has been shown in qualitative analyses of caregivers,
patient decisions about HF treatment preferences may
be impacted by caregiver understanding of disease.8
The HF caregiver’s role has become increasingly complex with advances in medical and surgical treatments
for HF, as acknowledged by a recent American Heart
Association Scientific Statement on family caregiving
in HF.9

METHODS
The data that support the findings of this study are
available from the corresponding author on reasonable request.

Study Population
REVIVAL is a prospective, observational, multicenter
cohort of ambulatory patients with advanced HF that
also includes caregivers.14 Patients and caregivers
were enrolled from 21 centers between July 2015
and June 2016. Patients enrolled were aged 18 to
80 years with New York Heart Association functional
class II to IV limitations for at least 45 of the previous
60 days, left ventricular ejection fraction ≤35%, and a
HF diagnosis >12 months. All patients were on maximum tolerated doses of evidence-based HF medical
and electrical therapies for ≥3 months or had a documented contraindication or intolerance to medication
use. In addition, enrollment required subjects to have
1 high-risk feature for mortality (ie, reduced peak oxygen uptake, reduced 6-minute walk distance, elevated
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natriuretic peptide level, reduced serum sodium, decreased Seattle Heart Failure Model 1-year predicted
survival, or active United Network for Organ Sharing
status 2 heart transplant), 1 unplanned HF hospitalization in the prior 12 months with a lesser threshold
for natriuretic peptide level, or 2 unplanned HF hospitalizations in the prior 12 months (Tables S1 and
S2). Patient participants were enrolled in REVIVAL at
the initial baseline A visit, and caregivers were subsequently identified and enrolled at the baseline B
visit (≈2 months later). Patients were determined to
have participating caregivers if the patient completed a baseline B visit and a caregiver was enrolled
at that visit with completion of at least one baseline
HRQOL survey. An independent Observational Study
Monitoring Board oversaw the conduct of REVIVAL.
The Institutional Review Board at each center approved the study. All subjects (patients and caregivers) provided written informed consent before study
participation.

Data Collection and Outcomes

Downloaded from http://ahajournals.org by on August 12, 2021

Patients were followed up for 24 months or until
earlier death, heart transplantation, or implantation
of durable mechanical circulatory support. Clinical
evaluation occurred at enrollment (baseline A), and at
2 (baseline B), 6, 12, 18, and 24 months. The following data were collected for patients at the baseline B
visit: demographics, clinical characteristics, medications, laboratory values, physical examination results,
and a 6-minute walk test. INTERMACS (Interagency
Registry for Mechanically Assisted Circulatory
Support) patient profiles were assigned at each visit
by the treating cardiologist, according to methods
previously described.15 Outcomes prospectively collected at the time of occurrence included hospitalizations, heart transplantation, mechanical circulatory
support, and death. At study entry and each visit,
patients were asked to read a 2-page document containing a basic description and illustration of an LVAD,
along with information about indications, benefits,
and complications of LVAD therapy.16 The description
of LVAD therapy was written at a US eighth-grade
education level (Flesch-K incaid readability ease). The
probabilities of survival, recurrent hospitalization, and
adverse events following LVAD included in the instrument were based on event rates of approved devices
at the time of survey development in 2015. Subjects
were then asked to reply on a Likert-type scale to
the question: “Based on how you feel right now, how
would you feel about having a VAD placed to treat
your heart failure?” Subjects were classified into 3
groups based on their responses: (1) wanting LVAD
(including “definitely want” and “probably want”),
(2) unsure, and (3) not wanting LVAD (including
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“probably not want” and “definitely not want”). Other
self-report instruments were administered as follows:
patients (at study entry [baseline A] and at 2 [baseline
B], 6, 12, 18, and 24 months) and caregivers (at study
entry at 2 months [baseline B], and at 6, 12, 18, and
24 months).

HRQOL and Burden Instruments
At each visit, patients were asked to complete
(via self-
report) 2 validated HRQOL instruments,
the Kansas City Cardiomyopathy Questionnaire
(KCCQ)17 and EuroQol Visual Analog Scale (EQ-
VAS).18 The KCCQ, an HF-
specific tool, consists
of 23 multiple-
choice questions with 7 domains:
Physical Limitations (6 items), Symptom Stability
(1 item), Symptom Frequency (4 items), Symptom
Burden (3 items), Self-Efficacy (2 items), Quality of
Life (3 items), and Social Limitations (4 items). The
Overall Summary Score is calculated as an average
of the Physical Limitations, Total Symptoms, Quality
of Life, and Social Limitations scores.17 Higher scores
(range, 0–100) reflect fewer limitations, lower symptom frequency and burden, and better HRQOL. The
EQ-
VAS score measures self-
rated overall health
(range, 0–100) wherein end points are labeled “best
imaginable health state” (higher score) and “worst
imaginable health state” (lower score). An EQ-VAS
score <55 has been considered to represent poor
HRQOL in ambulatory advanced HF, and was thus
used as a measure of HRQOL in this study.19 Prior
studies have considered clinically important changes
in score on the KCCQ and EQ-VAS to be 5 and 10
points, respectively.20,21 At enrollment, patients were
also administered the Personal Health Questionnaire,
an 8-question validated measure that screens for depression.22 Caregivers also completed the EQ-VAS.
In addition, caregiver burden was assessed using the
validated Oberst Caregiving Burden Scale (OCBS),
which measures 15 caregiving physical and emotional tasks in 2 domains (time spent on task and
difficulty of task) using 5-point Likert scales: for time:
1=none to 5=a great amount of time; and for difficulty: 1=not difficult to 5=extremely difficult.23

Statistical Analysis
Both patient and caregiver demographic and clinical characteristics were summarized as counts and
percentages for categorical data and median and
interquartile range (IQR) for continuous data. Patient
characteristics were compared between groups with
and without participating caregivers using χ2 tests
for categorical data and Wilcoxon rank-sum tests for
continuous data. Linear mixed model analyses of patient HRQOL (EQ-VAS and KCCQ) as well as caregiver
HRQOL (EQ-VAS) and caregiver burden (OCBS time
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and difficulty) were performed, with time (study visits)
as a continuous variable (visits number 1 [baseline A]
to 6 [month 24]) and with adjustment for baseline values, to assess their longitudinal effects. The analyses
of patient HRQOL were performed with (1) all enrolled
patients (n=400), (2) patients who completed a baseline B visit (n=337) as these were the patients eligible for caregiver enrollment, or (3) the subset of those
patients with a participating caregiver (n=95) as indicated. For the purposes of the longitudinal HRQOL
analysis of patients, patient baseline instrument score
(ie, KCCQ or EQ-VAS) was considered that obtained
at patient enrollment (baseline A visit), whereas for
caregiver analyses, patient baseline scores were considered those obtained at time of caregiver enrollment
(baseline B visit). Univariable and multivariable linear
mixed model analyses of caregiver EQ-VAS scores
were conducted with patient and caregiver characteristics as predictors. Cross-sectional (at baseline B)
effects of patient and caregiver characteristics on caregiver HRQOL and caregiver burden were assessed
using univariable and multivariable regression analyses. The following patient characteristics were included as predictors based on known contributions to
patient severity of illness and patient-caregiver relationship: EQ-VAS, KCCQ, frailty, gait speed, and Seattle
Heart Failure Model score. Caregiver characteristics
included: relationship to patient (versus spouse/domestic partner), paid employment, educational level
(versus less than high school), number of surgeries,
female sex, race (White compared to nonWhite race),
and marital status. Univariable and multivariable linear
mixed model analyses of patient HRQOL were conducted with caregiver characteristics as predictors:
educational level, female sex, marital status, EQ-VAS,
and OCBS time and difficulty scores.
Univariable repeated measures logistic regression
analysis was performed to assess which caregiver
baseline characteristics were related to patient preference for LVAD therapy. To this end, the 5-level patient
preference for LVAD therapy was dichotomized into
“yes, I want an LVAD placed to treat my HF” (from categories: definitely and probably want) and “no, I don’t
want an LVAD” (from categories: “not sure,” “definitely
not,” and “probably not”). The composite clinical outcome included the following patient outcomes, which
were combined for analysis because of low numbers
of individual events: first unplanned HF-related hospitalization, heart transplantation, durable mechanical circulatory support, and death. Univariable and
multivariable linear mixed model analyses of patient
HRQOL (EQ-
VAS and KCCQ) and Cox regression
analysis of time to the composite outcome were performed to ascertain which caregiver baseline characteristics were related to these patient outcomes.
The corresponding multivariable analyses of these 3
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patient outcomes (ie, generalized linear mixed model
analyses of patient preference for LVAD therapy and
linear mixed model analyses of patient HRQOL as well
as Cox regression analysis of time to the composite
outcome) were also performed versus caregiver participation, INTERMACS profile, and their interactions.
In the latter case, a time trend term for INTERMACS
was included in the model because of failure of the
hazard proportionality assumption. To assess potential bias resulting from missing caregiver data, Fisher
exact and 2-
sample Wilcoxon tests were used to
compare selected categorical and continuous patient
and caregiver characteristics between the groups
with missing and nonmissing caregiver HRQOL and
burden data, respectively. To further assess survivorship bias and the potential effects of missing data
on HRQOL and burden assessments, we used the
Wilcoxon rank-
sum test to compare differences in
baseline HRQOL (patients and caregivers) and burden
(caregivers) between those patients who did and did
not meet any study end point.
Characteristics with P<0.15 in all above univariable
analyses were entered into the corresponding stepwise multivariable analyses, and those variables with
P<0.05 were considered statistically significant in the
final multivariable models. No adjustments were made
for multiple hypotheses testing. Analyses were performed using SAS version 9.4 (Cary, NC).

RESULTS
Study Cohort
A total of 400 patients with ambulatory advanced
HF were enrolled in REVIVAL. Over the length of the
REVIVAL study, 61 subjects died, 57 subjects received
a durable LVAD, and 30 subjects underwent heart
transplantation (23 as a United Network for Organ
Sharing status 1A or 1B and 7 as a status 2). Of the 400
patients, 337 completed a baseline B visit, of which 95
had participating caregivers. The clinical outcomes of
subjects based on whether they completed baseline B
visits are depicted in Figure 1.
Table 1 describes baseline characteristics of patients with (n=95) and without (n=242) participating
caregivers. Patients with participating caregivers were
more frequently older and White race, and more had
a postgraduate degree, compared with those without
participating caregivers. There were no differences in
HF severity based on INTERMACS profile, New York
Heart Association functional class, or Seattle Heart
Failure Model score. Participating caregivers (n=95)
were mostly women, White race, and the spouse or
domestic partner of the patient (Table 2).
Forty-three caregivers did not have end of study
EQ-
VAS or OCBS assessments for the following
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Figure 1. REVIVAL (Registry Evaluation of Vital Information for VADs [Ventricular Assist Devices] in Ambulatory Life)
enrollment flowchart.
*Caregivers who signed informed consent and completed at least one baseline quality-of-life survey. INTERMACS indicates Interagency
Registry for Mechanically Assisted Circulatory Support; MCS, mechanical circulatory support; TXP, transplant; and UNOS, United
Network for Organ Sharing.

reasons: 15 patients died, 8 patients received an
LVAD, 4 patients withdrew consent, 3 caregivers
were withdrawn because of investigator withdrawal
of study subject, 1 caregiver withdrew consent (while
the patient remained in study), and 12 were otherwise
lost to follow-up for unknown reasons. Differences in
patient and caregiver baseline characteristics based
on caregiver missingness at 24 months are presented

in Table S3. Patients with missing caregiver HRQOL
and burden data were significantly younger than those
without missing caregiver data. There were more female caregivers in the missing group compared with
the nonmissing group. There were no differences in
baseline HRQOL (patients or caregivers) and burden
(caregivers) scores based on whether patients experienced the composite study end point (death, durable
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Table 1. Patient Characteristics by Caregiver Participation
Caregiver Participation

Characteristic
Age, y

No
(n=242)

Yes
(n=95)

Total
(n=337)

P Value

61 (52 to 67)

64 (57 to 71)

62 (54 to 68)

0.004*

0.15

Sex
Women

67 (27.7)

19 (20)

86 (25.5)

175 (72.3)

76 (80)

251 (74.5)

Black

69 (28.5)

10 (10.5)

79 (23.4)

White

155 (64.0)

83 (87.4)

238 (70.6)

Other

18 (7.4)

2 (2.1)

20 (5.9)

Men
Race

0.0001*

Ethnicity
Hispanic or Latino

26 (10.7)

2 (2.1)

28 (8.3)

Non-Hispanic or non-L atino

208 (86)

93 (97.9)

301 (89.3)

8 (3.3)

0 (0)

8 (2.4)

Unknown/undisclosed

0.006*

Education
Grade school (grades 1–8)

8 (3.3)

0 (0)

8 (2.4)

High school

65 (26.9)

26 (27.4)

91 (27)

Attended college/technical school

60 (24.8)

28 (29.5)

88 (26.1)

Associate degree

17 (7.0)

7 (7.4)

24 (7.1)

Bachelor degree

30 (12.4)

11 (11.6)

41 (12.2)

Postgraduate degree

0.035*
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13 (5.4)

13 (13.7)

26 (7.7)

Unknown

49 (20.2)

10 (10.5)

59 (17.5)

Ischemic cardiomyopathy

104 (43.0)

43 (45.3)

147 (43.6)

0.70

Diabetes mellitus (n=336)

91 (37.8)

34 (35.8)

125 (37.2)

0.74

Atrial fibrillation (n=331)

92 (39.0)

40 (42.1)

132 (39.9)

0.6

Heart failure diagnosis >5 y

134 (55.4)

56 (58.9)

190 (56.4)

0.55

Not frail

94 (48.2)

39 (43.8)

133 (46.8)

0.02*

Prefrail

61 (31.3)

41 (46.1)

102 (35.9)

Frail

40 (20.5)

9 (10.1)

49 (17.3)

Frailty (n=284)

NYHA class
I

7 (2.9)

4 (4.2)

11 (3.3)

II

84 (34.7)

28 (29.5)

112 (33.2)

III

117 (48.3)

52 (54.7)

169 (50.1)

IIIb

22 (9.1)

8 (8.4)

30 (8.9)

IV

12 (5)

3 (3.2)

15 (4.5)

1 (0.4)

0 (0)

1 (0.3)
3 (0.9)

0.73

INTERMACS profile
2
3

1 (0.4)

2 (2.1)

4

21 (8.7)

6 (6.3)

27 (8)

5

44 (18.2)

24 (25.3)

68 (20.2)

6

78 (32.2)

29 (30.5)

107 (31.8)
131 (38.9)

7

0.40

97 (40.1)

34 (35.8)

PHQ ≥10 (+depression screen) (n=306)

53 (24.8)

22 (23.9)

75 (24.5)

0.87

Left ventricular ejection fraction (n=319)

28.08 (23 to 33.4)

29.0 (23.2 to 33)

28.5 (23 to 33.4)

0.87

6-MWD, m (n=299)

361.4 (280 to 416)

364.2 (300.2 to 417)

362.7 (292.6 to 417)

0.89

1 (0 to 2)

0 (0 to 1)

1 (0 to 2)

0.40

No. of heart failure hospitalizations

(Continued)
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Table 1. Continued
Caregiver Participation

Characteristic
BMI, kg/m2

No
(n=242)

Yes
(n=95)

Total
(n=337)

P Value

29.5 (25.3 to 35.1)

28.5 (25.2 to 33.4)

29.1 (25.3 to 34.4)

0.68

EQ-VAS score(n=305)

70 (50 to 80)

70 (50 to 80)

70 (50 to 80)

0.78

KCCQ (n=308)

66 (51 to 81)

63 (43 to 77)

66 (48 to 80)

0.26

0.45 (−0.2 to 1.1)

0.7 (−0.3 to 1.2)

0.5 (−0.2 to 1.2)

0.43

Seattle Heart Failure Model score

Number (percentage) and χ P values are given for categorical characteristics, and median (interquartile range) and Wilcoxon rank-sum P values are given
for continuous characteristics. 6-MWD indicates 6-minute walk distance; BMI, body mass index; EQ-VAS, EuroQol Visual Analog Scale (range, 0 [worst health
state] to 100 [best health state]); INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; KCCQ, Kansas City Cardiomyopathy
Questionnaire overall summary score (range, 1 [worse] to 100 [better]); NYHA, New York Heart Association; and PHQ, personal health questionnaire.
*Significant P value < 0.05.
2

mechanical circulatory support, or heart transplantation) (Table S4).

Patient and Caregiver HRQOL and Burden
Over Time
When examining the baseline A patient cohort (n=400),
patient HRQOL, as measured using the EQ-VAS score
and KCCQ Overall Summary Score, demonstrated
Table 2. Baseline Characteristics of Participating
Caregivers
Characteristic
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Age, y

Value
62 (50–68)

Sex
Women

76 (81.7)

Men

17 (18.3)

Race
Black

8 (8.7)

White

82 (89.1)

Other

2 (2.2)

Relationship to patient
Spouse/domestic partner

72 (76.6)

Son/daughter

8 (8.5)

Other family member

8 (8.5)

Friend

3 (3.2)

Other
Employed

3 (3.2)
45 (49.5)

Marital status
Married

82 (87.2)

Single

7 (7.4)

Widowed

3 (3.2)

Divorced/separated

2 (2.1)

Oberst Caregiver Burden Scale
Time spent average score
Difficulty average score

2.2 (1.7–2.8)
1.1 (1–1.5)

Data are given as number (percentage) for categorical characteristics and
median (interquartile range) for continuous characteristics. Oberst Caregiver
Burden Scale time spent on task: 1=none to 5=a great amount of time; and
difficulty of task: 1=not difficult to 5=extremely difficult.

improvement over time. At baseline A (patient enrollment), the median patient EQ-VAS score was 65 (IQR,
50–75) and KCCQ score was 64 (IQR, 48–78). By the
24-month visit, the patient KCCQ score increased by
a median of 3 points (IQR, −7 to 13 points), whereas
the EQ-VAS score increased by a median of 5 points
(IQR, −5 to 17 points). In a linear mixed model adjusting
for scores at time of patient enrollment, both EQ-VAS
scores (estimate, 0.88; 95% CI, 0.44–1.32; P<0.0001)
and KCCQ score (estimate, 0.49; 95% CI, 0.13–0.84;
P=0.007) increased significantly, demonstrating longitudinal improvement in HRQOL that was dependent on
baseline values. This result remained significant when
further adjusted for INTERMACS profile (Table 3). We
repeated the above analysis for those patients (n=337)
completing a baseline B visit, the visit at which caregivers were enrolled, and found similar results. When
adjusted for INTERMACS profile, both patient EQ-VAS
(P=0.0006) and KCCQ (P=0.016) scores improved
over time (Table 3).
Participating caregivers’ overall HRQOL (EQ-
VAS) and burden (OCBS) were assessed at baseline B and follow-
u p. Baseline caregiver median
EQ-VAS was 90 (IQR, 76–9 0). Baseline caregiver
OCBS scores for each of the 15 items addressing
time on task and difficulty of task are described in
Figure S1. The 3 items with the most time spent on
tasks were emotional support, providing transportation or “company,” and watching for/monitoring
symptoms and progress. The tasks identified as
most difficult were managing finances/forms related to illness, performing additional household
tasks for the patient, and managing patient behavior problems. Although OCBS scores did not
change significantly from baseline to end of study
(Figure 2), caregivers scored “time spent on tasks”
higher than they scored “difficulty of tasks” at both
time points. Median change in caregiver instrument
scores from baseline to 24-month follow-u p among
those 51 caregivers with these data available were
as follows: EQ-VAS, 0 (IQR, −5 to 5; P=0.77); mean
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5.12
(2.05 to 8.19)
7.61
(4.57 to 10.65)

INTERMACS 6 vs 1–4

INTERMACS 7 vs 1–4

<0.0001

0.001

0.244

<0.0001

11.99
(9.50 to 14.48)

7.91
(5.41 to 10.4)

4.46
(1.86 to 7.06)

<0.0001

<0.0001

0.0008

<0.0001

0.025*

<0.0001

P Value

7.67
(4.50 to 10.83)

5.18
(1.99 to 8.38)

1.50
(−1.88 to 4.88)

0.80
(0.34 to 1.25)

0.62
(0.57 to 0.68)

Estimate
(95% CI)

P Value

<0.0001

0.002

0.384

<0.0001

0.0006*

<0.0001

EQ-VAS(n=313)

KCCQ (n=317)

12.14
(9.54 to 14.73)

8.02
(5.41 to 10.63)

4.33
(1.61 to 7.05)

0.44
(0.08 to 0.80)

0.78
(0.73 to 0.82)

Estimate
(95% CI)

Baseline B Cohort (n=337)

<0.0001

<0.0001

0.002

<0.0001

0.016*

<0.0001

P Value

EQ-VAS indicates EuroQol Visual Analog Scale; HRQOL, health-related quality of life; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; and KCCQ, Kansas City Cardiomyopathy
Questionnaire overall summary score.
*Significant P value < 0.05.

1.92
(−1.31 to 5.15)

INTERMACS 5 vs 1–4

INTERMACS profile overall effect

0.0006*

0.39
(0.05 to 0.74)

0.77
(0.33 to 1.21)

Estimate
(95% CI)

Time

<0.0001

P Value

0.79
(0.75 to 0.84)

0.64
(0.59 to0.69)

Estimate
(95% CI)

KCCQ (n=373)

KCCQ, baseline A

EQ-VAS, baseline A

Variable

EQ-VAS(n=367)

Baseline A Cohort (n=400)

Table 3. Longitudinal Analysis of Patient HRQOL Over Time, Adjusted for Baseline Values and INTERMACS Profile in Total Baseline A Patient Cohort and Also Those
Patients Completing a Baseline B Visit
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Figure 2. Caregiver mean time (n=51) and difficulty (n=52) summary scores at baseline (black
bars) and end of study 24-month follow-up (white bars) on the Oberst Caregiving Burden Scale
(OCBS).
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OCBS time score, 0 (IQR, −0.33 to 0.33; P=0.93);
and mean OCBS difficulty score, 0 (IQR, −0.2 to
0.23; P=0.58). Caregiver overall HRQOL and burden
did not demonstrate change over time in a linear
mixed model with time as a continuous variable and
with adjustment for baseline scores (Table 4).

Baseline Characteristics Related to
Caregiver HRQOL
In cross-sectional analysis at the time of caregiver enrollment (baseline B visit), a higher patient KCCQ overall summary score was significantly associated with a
higher caregiver EQ-VAS score (estimate, 0.18; 95%
CI, 0.05–0.31; P=0.007), less caregiver OCBS time (estimate, −0.02; 95% CI, −0.02 to −0.01; P<0.0001), and
less caregiver OCBS difficulty (estimate, −0.01; 95%
CI, −0.01 to −0.004; P=0.0007).
In the longitudinal multivariable analysis of patient and caregiver characteristics on the outcome
of caregiver overall HRQOL, adjusted for the baseline caregiver EQ-VAS score, a higher patient time-
dependent KCCQ overall summary score (estimate,
0.10; 95% CI, 0.01–0.19; P=0.034) and being a married caregiver (estimate, 7.05; 95% CI, 1.34–
12.8;
P=0.016) were independently associated with higher

caregiver overall HRQOL (Table 5). Of note, of the 82
caregivers who were married, 72 were spouses of
the patient.

Caregiver Characteristics Related to
Patient HRQOL and Outcomes Over Time
In the multivariable analysis, higher patient EQ-
VAS
scores were associated with higher caregiver EQ-VAS
scores over time (estimate, 0.26; 95% CI, 0.15–0.37;
P<0.0001), whereas lower patient EQ-VAS scores were
significantly related to higher caregiver mean OCBS
time scores (estimate, −5.43; 95% CI, −8.25 to −2.62;
P=0.0002). Similarly, worse patient KCCQ overall summary scores were correlated with higher caregiver
mean OCBS time scores (estimate, −10.6; 95% CI,
−13.3 to −7.8; P<0.0001).

Factors Related to Patient Preferences
for LVAD Therapy and Composite Patient
Clinical Outcomes
Patients with participating caregivers (versus without)
had a higher odds of a “yes” response for preference
for LVAD therapy over time (odds ratio, 1.43; 95% CI,
1.03–1.99; P=0.034), adjusted for time-
dependent

J Am Heart Assoc. 2021;10:e019901. DOI: 10.1161/JAHA.120.0199019

Gilotra et al

Heart Failure Caregiver Quality of Life Over Time

Table 4. Longitudinal Model of Caregiver HRQOL (Measured Using EQ-VAS) and Burden (Measured Using OCBS) Over
Time, Adjusted for Baseline Values
EQ-VAS

Variable
EQ-VAS, baseline

OCBS Mean Difficulty

Estimate
(95% CI)

P Value

0.64 (0.49 to 0.79 )

<0.0001*

OCBS mean difficulty,
baseline

Estimate
(95% CI)

P Value

0.72 ( 0.63 to 0.82)

<0.0001*

OCBS mean time,
baseline
Time

0.003 (−1.12 to 1.12 )

0.996

0.019 (−0.01 to 0.05)

0.179

OCBS Mean Time
Estimate
(95% CI)

P Value

0.74 ( 0.64 to 0.84)

<0.0001*

−0.0004 (−0.04 to 0.04 )

0.985

EQ-VAS indicates EuroQol Visual Analog Scale; HRQOL, health-related quality of life; and OCBS, Oberst Caregiver Burden Scale.
*Significant P value < 0.05.
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INTERMACS profile (P>0.05). Of those with a participating caregiver, 5 of 32 (16%) patients who had an
initial preference of “yes” for LVAD underwent LVAD
implantation during study follow-up (additional 2 were
transplanted), whereas 8 of 59 (14%) of those saying
“no” underwent LVAD (additional 2 were transplanted).
For patients with a participating caregiver, the risk of
experiencing the composite clinical outcome event
(first unplanned HF-related hospitalization, heart transplantation, LVAD placement, or death) was assessed in
a multivariable Cox proportional hazard model including INTERMACS profile and baseline participating caregiver characteristics. Both worsening INTERMACS
profile (hazard ratio [HR], 1.52; 95% CI, 1.13–
2.04;
P=0.005) and having a nonmarried participating caregiver (HR, 2.99; 95% CI, 1.29–
6.96; P=0.011) significantly increased the hazard of a patient having an
event.

DISCUSSION
Among ambulatory patients with advanced HF, we
determined that: (1) patient HRQOL improved over
time when adjusted for the baseline value, whereas
participating caregiver HRQOL and burden did not,
contrary to our hypothesis that these would worsen
over time; (2) caregiver HRQOL and burden were
positively associated with patient HRQOL, as hypothesized; and (3) having a participating caregiver
increased likelihood of patient preference for LVAD
therapy, whereas having a nonmarried participating
Table 5. Longitudinal Analysis of Caregiver HRQOL Over
Time, Adjusted for Baseline Values
Variable

Estimate (95% CI)

P Value

Caregiver EQ-VAS

0.61 (0.45–0.77)

<0.0001

Patient KCCQ

0.10 (0.01–0.19)

0.034

Caregiver marital status

7.05 (1.34–12.80)

0.016

EQ-VAS indicates EuroQol Visual Analog Scale; HRQOL, health-related
quality of life; and KCCQ, Kansas City Cardiomyopathy Questionnaire overall
summary score.

caregiver increased the risk of having a clinical
event. Although HRQOL in patients with HF and
cross-
s ectional caregiver HRQOL are well characterized in the literature, we describe, for the first
time, longitudinal HRQOL and burden of caregivers
of an ambulatory cohort of patients with advanced
HF.

Patient HRQOL
Patients with HF have poor HRQOL when compared
with those without HF.24 More important, HRQOL is
associated with other HF-
related outcomes, with
improvement in HRQOL being associated with better event-free survival.25 In our overall cohort of ambulatory patients with advanced HF, we found that
patient HRQOL significantly improved over time
among survivors when adjusted for baseline values by both the KCCQ and the EQ-VAS. Change
in patient HRQOL is linked to comorbidities26 as
well as HF symptom severity.27 Our study corroborates these prior findings as we showed that the
less severe the INTERMACS profile, the better the
patient HRQOL. When adjusted for INTERMACS
profile and presence of a caregiver, EQ-VAS scores
continued to improve over time, whereas KCCQ
overall summary scores did not. This may be attributable to differences in the measures (ie, the EQ-
VAS is a generic instrument, whereas the KCCQ is
an HF-s pecific instrument). Also, the EQ-VAS is a
single item measuring overall HRQOL, whereas the
KCCQ overall summary score is derived from multiple items and domains. More important, although
change over time was seen in the KCCQ (median
increase, 3 points) and EQ-VAS (median increase, 5
points), these changes were small relative to what is
considered a minimal clinically important difference
in these scores (5 and 10 points, respectively).20,21
However, the lack of either clinically or statistically significant deterioration in these measures of
HRQOL in survivors over the 2-year course of the
study is also notable.
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Caregivers play a fundamental role in the care of
patients with HF, including personal and emotional
care.2,28 Increased caregiver burden is associated
with poor health outcomes for caregivers and patients
alike,6,29 although interestingly, results of prior studies have also demonstrated an association between
higher caregiver burden and lower patient clinical event
risk.30 In our study, using the OCBS, caregivers experienced higher burden with time spent rather than difficulty of tasks, with time providing emotional support
being highest. The latter finding has been reported in
other studies of caregiving in HF.7 Caregiver burden
did not increase over time, contrary to our hypothesis
that caregiver burden increases over time in patients
with advanced stages of HF. Pressler and colleagues
demonstrated in a general ambulatory HF cohort (with
10% loss to follow-up attributable to death/severity of
illness) that caregiver burden, also measured using
the OCBS, actually improved over a 9-year period.7 In
Pressler’s study, the Medical Outcomes Study Short
Form-12 was used to demonstrate lack of worsening
in caregiver HRQOL. We also did not find a significant
decline in caregiver HRQOL using the EQ-VAS.
Potential explanations for our findings that caregiver
HRQOL and burden did not worsen over time include:
(1) REVIVAL was composed of a HF cohort that, based
on inclusion criteria, already had medically advanced
disease at time of patient and caregiver enrollment; (2)
there was a survivorship effect, with loss of follow-up
data on a substantial proportion of sicker patients
who went on to meet clinical end points (although one
would still have expected deterioration of clinical status, including quality of life, among survivors), which
decreased caregiver participation over time; and (3)
caregivers may not perceive their care for patients as
burdensome or may adapt over time to caregiving related tasks, making the perceived burden low and unchanging, which may also impact caregiver HRQOL in
a positive way.
Our study uniquely aimed to describe the effects of
caregiver and patient baseline characteristics on overall
caregiver HRQOL over time. Among patients with participating caregivers, we found that caregiver HRQOL
and burden were better when patient HRQOL was better, at baseline and longitudinally. In the HF literature,
better caregiver HRQOL and lower burden have been
described for patients with less severe HF symptoms,
which ultimately also affect patient HRQOL. Studies
have demonstrated conflicting results on the relationship of a caregiver or spouse’s HRQOL with a patient’s
HRQOL.30,31 Our and prior findings highlight the complex interdependence between patient and caregiver
HRQOL, which may also depend on changes over time
in patient and caregiver health status. In addition, the
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dynamic effect of patient HRQOL on caregiver HRQOL
and vice versa most likely results in a bidirectional relationship on HRQOL over time.
We also found that caregiver HRQOL was better
over time when caregivers were married, but not otherwise associated with several caregiver characteristics. The positive effect of marital status on caregiver
HRQOL (noting that most married caregivers in our
study were partners of the patient) deserves further
study, as we did not measure “quality” of the marital
relationship. Although studies to date do not describe
health of a spouse as impacting HF outcomes in patients,31 the health of a patient with HF has been shown
to impact the caregiving partner.32

Factors Related to Patient Clinical
Outcomes and Preferences for LVAD
Therapy
Patient HRQOL is associated with HF clinical outcomes. In the nonrandomized ROADMAP (Risk
Assessment and Comparative Effectiveness of Left
Ventricular Assist Device and Medical Management)
study, among subjects with worse HRQOL (EQ-VAS
score, <55), survival on the original therapy was lower
with medical management than with ambulatory LVAD
therapy.19 From REVIVAL, our group has recently described that patients with worse baseline KCCQ scores
were more likely to prefer LVAD therapy.16,33 Therefore,
in addition to standard clinical risk factors, patient-
reported outcomes, such as HRQOL, should be incorporated into shared decision making on advanced HF
therapies. The addition of longitudinal assessment of
patient HRQOL in HF may lend even further insight.
We found that the presence of a participating caregiver was the only assessed caregiver characteristic that
was predictive of patient preference for LVAD therapy. As
noted above, although we cannot speak to the quality of
the caregiver-patient relationship, perhaps patients with
participating caregivers had more engaged, supportive
caregivers, which may have influenced their inclination
to undergo LVAD implantation. In a recent analysis of the
entire REVIVAL cohort, we demonstrated that patient
socioeconomic status influenced preference for LVAD
therapy, with patients more likely to prefer LVAD therapy
if they had a lower income or lower education level.16
In the present study, patients who had a participating
caregiver were more likely to both prefer LVAD therapy
and have a higher education level compared with patients without a participating caregiver. The reason for
these discrepant findings on education level and LVAD
preference are unclear and may be influenced by the
presence of a participating caregiver. Further investigation into better understanding the interplay of socioeconomic factors and caregiver role in patient preferences
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for advanced HF therapies is warranted. Notably, having a nonmarried caregiver increased patient risk of
reaching a clinical end point, independent of HF severity based on INTERMACS profile. This finding requires
further study, as the number of nonmarried caregivers
in our study was small and included individuals with a
variety of relationships with the patient.
This study has several important limitations.
Patients were recruited from centers with HF programs
and therefore may not be representative of all patients
with ambulatory advanced HF. Patients and caregivers
were also enrolled at different baseline visits; patients
were enrolled 2 months earlier than caregivers, which
may influence outcomes and result in selection bias.
Caregivers included in this study may not be representative of all patient caregivers who existed, for several
reasons. First, a low proportion of REVIVAL advanced
HF patient cohort had a participating caregiver in the
registry, and there was dropout in caregiver participation over time. This limitation resulted in a moderately
small caregiver sample size. Furthermore, caregivers
lacked diversity (ie, predominantly women, White race,
and spouses), which reduced generalizability. Lack
of participating caregivers may reflect caregiver time
constraints or disinterest and does not exclude the
presence of an actively engaged caregiver. We also
do not know about the quality of the caregiver-patient
relationship. These limitations importantly highlight
challenges that exist in conducting caregiver research.
Future research to elucidate reasons for low caregiver
participation and improve caregiver recruitment is warranted. More important, the results of this study pertain only to patients surviving the duration of the study
and their caregivers. The association between worse
INTERMACS profile (ie, sicker patients) and meeting a
clinical end point (death, transplant, or LVAD) is well
established. Therefore, the sickest patients and their
caregivers are missing from longitudinal HRQOL assessments, which likely contributes to overestimation
of HRQOL over time. Interestingly, we noted that female caregivers were less likely to have complete
study data at 24 months, and a significant proportion
of missing caregiver data was attributable to patients
meeting clinical end points earlier in the study. One
could hypothesize that sex differences in rates of HF
outcomes played a role in these observed differences.
However, notably, prior work from the REVIVAL cohort demonstrated that women and men had similar
HF profiles as well as 1-year combined risk of death,
LVAD, or transplantation (24% versus 22%; P=0.94).34

CONCLUSIONS
In an ambulatory cohort of patients with advanced HF,
we found that surviving patients’ HRQOL improved
modestly over time and that caregivers’ HRQOL and
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burden did not change. Having a participating, married
caregiver was associated with an increased patient
willingness to consider ambulatory LVAD therapy and
a lower composite risk of death, urgent transplant, or
ventricular assist device. These data highlight the need
for more research on the central role of the caregiver-
patient relationship on longitudinal outcomes and decision making in advanced HF.
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Table S1. REVIVAL Inclusion Criteria.
1. Ambulatory.
2. Chronic systolic heart failure ≥ 12 months.
3. NYHA II - IV for at least 45 of the last 60 days.
4. Last documented left ventricular ejection fraction ≤ 35% by any imaging modality.
5. Age 18 - 80 years.
6. Currently under the care of a cardiologist at study site.
7. On appropriate evidenced -based heart failure medications – ACE inhibitor, ARB or
sacubitril--valsartan; beta blocker; aldosterone antagonist; hydralazine/long-acting nitrate
[required of African-American subjects only] for ≥ 3 months absent contraindications or
intolerances.
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8. Has ICD or CRT-D. If CRT-D, present for ≥ 3 months.
9. Demonstrated advanced heart failure, including any of the following*:
i.Serum sodium ≤ 135 mEq/L (obtained as an outpatient)**
ii.Serum BNP ≥ 750 pg/mL or NT-proBNP ≥ 3000 pg/mL** (obtained as an outpatient)
iii.Seattle Heart Failure Model (SHFM) one year predicted survival ≤ 85%**
iv.Heart Failure Survival Score (HFSS) ≤ 7.19**
v.Peak VO2 ≤ 55% of predicted for age by Wasserman equation or ≤ 14 ml/kg/min, with
RER ≥ 1.05 ***
vi.VE/VC02 slope > 40***
vii.6-minute walk test (6MWT) distance ≤ 350 m without significant non-cardiac
limitation**

viii.Currently listed as Heart Transplant Status 2 due to heart failure limitation OR History
of one (1) hospitalization (≥ 24 hours) for acute or acute on chronic heart failure in the
past year with either serum BNP ≥ 500 pg/mL or NT-proBNP ≥ 2000 pg/mL**
(obtained as an outpatient)
10. History of two (2) hospitalizations (≥ 24 hours) for acute or acute on chronic heart failure in the past
year.
11. Willingness to continue to receive heart failure care from the enrolling advanced heart failure clinic
over the next two (2) years and to come for all scheduled study visits.
12. Written Informed consent given.

* Qualifying measure must be the most recent of that type of measure obtained (i.e., a BNP ≥
1000 obtained 2 months prior would not qualify the heart failure subject if a more recent BNP
Downloaded from http://ahajournals.org by on August 12, 2021

was < 1000)
**Using values obtained within the prior 90 days, except for peak VO2 within 365 days
***Obtained within the prior 365 days

Table S2. REVIVAL Exclusion Criteria.
1. Known serious medical problem other than heart failure that would be expected to limit 2year survival (≥50% mortality within 2 years from non-heart failure diagnosis).
2. Patient is not likely to be compliant with the protocol, in the opinion of the Investigator.
3. Currently hospitalized.
4. Current use of an intravenous inotrope.
5. Primary functional limitation from non-cardiac diagnosis even if not likely to limit survival.
6. Chronic hemodialysis or peritoneal dialysis or serum creatinine value of ≥ 3 mg/dL at time of
enrollment.
7. Cardiac amyloidosis, cardiac sarcoidosis, constrictive pericardial disease, active myocarditis
or congenital heart disease with significant structural abnormality.
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8. Hypertrophic cardiomyopathy unless dilated LV and no outflow gradient.
9. Cardiac conditions that are amenable to surgical or percutaneous procedures (other than
VAD or transplant) that would substantially improve prognosis and for which this subject is
a reasonable candidate, regardless of whether the procedure will or will not be performed.
10. Uncorrected hyperthyroidism or hypothyroidism.
11. Pregnancy.

Table S3. Patient and Caregiver Baseline Characteristics by Caregiver EQ-VAS and OCBS
missingness at 24 months.
Missing

Not missing

(n=43)

(n=52)

59.6 (13.2)

64.5 (10.1)

p

PATIENT
Age, years
Sex

0.048
0.076

Male

38 (88.4)

38 (73.1)

Female

5 (11.6)

14 (26.9)

Race

0.441
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African-American/Black

6 (14.0)

4 (7.7)

White

37 (86.0)

46 (88.5)

Other

0 (0.0)

2 (3.8)

New York Heart Association Class

0.773

I

1 (2.3)

3 (5.8)

II

15 (34.9)

13 (25.0)

III

22 (51.2)

30 (57.7)

IIIb

4 (9.3)

4 (7.7)

IV

1 (2.3)

2 (3.8)

6 minute walk distance (m)

342.5±105.2

362±88.4

0.417

Normalized peak VO2 (ml/kg/min)

14.49±4.43

14.61±4.19

0.853

Presence of ICD or CRT

23 (53.5)

27 (51.9)

1

Number of heart failure

1.00 (1.13)

0.79 (1.16)

0.246

56.8 (16.1)

60.5 (11.9)

0.272

hospitalizations
CAREGIVER
Age
Sex
Male
Female

0.014
3 (7)

14 (28)

40 (93)

36 (72)

Race

0.730
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African-American/Black

5 (11.9)

3 (6)

White

36 (85.7)

46 (92)

Other

1 (2.4)

1 (2)

Relationship to patient

0.123

Other

1 (2.3)

2 (3.9)

Friend

3 (7)

0 (0)

Other family member

6 (14)

2 (3.9)

Son/Daughter

3 (7)

5 (9.8)

30 (69.8)

42 (82.4)

Spouse/Domestic Partner

Data presented as mean (SD), or counts and percentages.
CRT, chronic resynchronization therapy; ICD, implantable cardiac defibrillator; VO 2: oxygen consumption

Table S4. Baseline health-related quality of life and burden based on patient meeting study
endpoint.
Patient outcome

Patient KCCQ

Without event

With event*

Median (P25,P75)

Median (P25-P75)

p

64.5 (49, 80), n=242

62 (46-76), n=131

0.07

70 (50, 75), n=238

60 (50, 75), n=129

0.16

64 (49, 80), n=214

63 (48, 77), n=103

0.22

69 (50-75), n=211

62.5 (50-75), n=102

0.55

85 (75, 90), n=65

90 (77.5, 94), n=32

0.39

Caregiver OCBS, time

2.27 (1.67, 2.77),

2.03 (1.80, 2.83),

0.74

(n=95)

n=61

n=30

Caregiver OCBS, difficulty

1.2 (1.00, 1.47), n=63

1.07 (1.00, 1.33),

(Baseline A cohort, n=400)
Patient EQ-VAS
(Baseline A cohort, n=400)
Patient KCCQ
(Baseline B cohort, n=337)
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Patient EQ-VAS
(Baseline B cohort, n=337)
Caregiver EQ-VAS
(n=95)

(n=95)

0.20

n=30

*Those with missing HRQoL data due to reaching study endpoint (Death, mechanical circulatory support or UNOS
1A/1B transplant)

Figure S1. Oberst Caregiving Burden Scale Scores*
Time on Task
Median
Mean (SD) (IQR)

Difficulty of Task
Mean
(SD)

Media
n
(IQR)
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1.

Medical or nursing treatments (giving medications, skin care, dressings, etc.)

1.80
(0.97)

2 (1-2)

1.21
(0.59)

1 (1-1)

2.

Personal care (bathing, toileting, getting dressed, feeding, etc.)

1.38
(0.84)

1 (1-1)

1.18
(0.61)

1 (1-1)

3.

Assistance with walking, getting in and out of bed, exercises, etc

1.55
(0.87)

1 (1-2)

1.18
(0.59)

1 (1-1)

4.

Emotional support, 'being there' for the patient

3.50
(1.12)

3 (3-5)

1.43
(0.74)

1 (1-2)

5.

Watching for and reporting the patient’s symptoms, watching how the patient
is doing, monitoring the patient's progress

3.06
(1.28)

3 (2-4)

1.36
(0.69)

1 (1-2)

6.

Providing transportation or 'company' (driving, riding along with patient,
going to appointments, driving patient around for errands, etc.)

3.21
(1.31)

3 (2-4)

1.38
(0.74)

1 (1-2)

7.

Managing finances, bills, and forms related to the patient's illness

2.80
(1.55)

2 (1-4)

1.48
(0.89)

1 (1-2)

8.

Additional household tasks for the patient (laundry, cooking, cleaning, yard
work, home repairs, etc.)

2.81
(1.37)

3 (2-4)

1.49
(0.85)

1 (1-2)

9.

Additional tasks outside the home for the patient (shopping for food and
clothes, going to the bank, running errands, etc.)

2.68
(1.37)

2 (2-3)

1.43
(0.74)

1 (1-2)

10. Structuring/ planning activities for the patient (recreation, rest, meals, things
for the patient to do, etc.)

2.22
(1.26)

2 (1-3)

1.31
(0.71)

1 (1-1)

11. Managing behavior problems (moodiness, irritability, confusion, memory
loss, etc.)

2.25
(1.14)

2 (1-3)

1.70
(1.02)

1 (1-2)

12. Finding and arranging someone to care for the patient while you are away

1.40
(0.80)

1 (1-2)

1.25
(0.66)

1 (1-1)

13. Communication (helping the patient with the phone, writing or reading,
explaining things, trying to understand what the patient is trying to say, etc.)

1.76
(1.10)

1 (1-2)

1.26
(0.65)

1 (1-1)

14. Coordinating, arranging, and managing services and resources for the patient
(scheduling appointments, arranging transportation, locating equipment and
services, and finding outside help)

1.90
(1.14)

1 (1-3)

1.31
(0.76)

1 (1-1)

15. Seeking information and talking with doctors, nurses, and other professional
health care workers about the patient's condition and treatment plans

2.52
(1.19)

2 (2-3)

1.35
(0.71)

1 (1-1)

*Three highest scoring items in each category are highlighted.

